Disc Medicine, Inc.

What they do

Disc Medicine is developing a pipeline of product candidates targeting heme biosynthesis and iron homeostasis. Lead programs include bitopertin (a GlyT1 inhibitor for erythropoietic porphyrias), selcodebart (an anti-hemojuvelin antibody for anemia of myelofibrosis and inflammatory bowel disease), and DISC-3405 (an anti-TMPRSS6 antibody for polycythemia vera and sickle cell disease). A preclinical candidate, DISC-0998, targets anemia associated with inflammatory diseases.

Revenue drivers

• No approved products — The company has no commercialized products and does not generate product revenue; all programs are in clinical or preclinical development.
• Bitopertin — Pipeline candidate for erythropoietic protoporphyria and X-linked protoporphyria; currently under FDA review (CRL issued) with Phase 3 APOLLO trial underway.
• Selcodebart (DISC-0974) — Pipeline candidate for anemia of myelofibrosis; Phase 2 data reported, EU Orphan Drug Designation received, end-of-Phase 2 FDA interaction expected in Q4 2026.
• DISC-3405 — Pipeline candidate for polycythemia vera and sickle cell disease; Phase 2 (RESTORE-PV) and Phase 1b studies underway.

Recent performance

For the second quarter of 2026, Disc Medicine reported cash, cash equivalents, and marketable securities of $717.7 million as of June 30, 2026. R&D expenses for the quarter were notable due to ongoing late-stage trials and manufacturing activities. Net losses have widened each year from $36.0 million in 2021 to $212.2 million in 2025. Operating cash flow also deteriorated, reaching negative $180.4 million in 2025. On the balance sheet, total assets were $735.1 million, liabilities $90.9 million, and long-term debt $59.3 million as of June 30, 2026.

Strategy

Disc Medicine is focused on executing pivotal clinical trials and regulatory submissions for its lead candidates. The company intends to address the FDA's CRL for bitopertin with results from the Phase 3 APOLLO trial, which completed enrollment at 183 patients. It is also advancing selcodebart towards a potential end-of-Phase 2 meeting and eventual pivotal-stage development, and progressing DISC-3405 through Phase 2 and Phase 1b studies. Management is expanding patient access through an Expanded Access Program for bitopertin, and continues to explore additional indications for its pipeline.

Risks

• Regulatory setback for bitopertin — The FDA issued a complete response letter in February 2026, concluding that Phase 2 data did not demonstrate a link between PPIX reduction and sunlight exposure-based endpoints, delaying potential approval.
• Dependence on APOLLO trial success — A successful Phase 3 APOLLO trial is needed to respond to the CRL and support traditional approval; failure could materially harm the company's prospects.
• No product revenue — The company has no approved products or revenue sources, and relies on external financing to fund operations.
• Clinical and financial risk of pipeline — All product candidates are in clinical or preclinical stages and carry inherent risks of safety, efficacy, and development delays; cash burn is increasing as trials advance.

Outlook

Management expects to report topline data from the Phase 3 APOLLO trial of bitopertin in Q4 2026 and, if successful, to submit a response to the CRL and receive an FDA decision by mid-2027. Additional data from the RALLY-MF trial of selcodebart and an end-of-Phase 2 FDA interaction are expected in Q4 2026. Initial data from the RESTORE-PV Phase 2 study of DISC-3405 is expected in Q3 2026, and Phase 1b sickle cell disease data in Q4 2026. Management states the current cash position provides runway into 2029.